FY2029 Earnings Estimate for CNTB Issued By Leerink Partnrs

Connect Biopharma Holdings Limited (NASDAQ:CNTB - Free Report) - Research analysts at Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for shares of Connect Biopharma in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith anticipates that the company will post earnings per share of ($0.19) for the year. The consensus estimate for Connect Biopharma's current full-year earnings is ($0.20) per share.

Connect Biopharma Trading Up 5.5 %

NASDAQ:CNTB traded up $0.05 on Friday, hitting $0.97. 1,832 shares of the company's stock traded hands, compared to its average volume of 17,535. Connect Biopharma has a 1 year low of $0.91 and a 1 year high of $2.66. The firm has a 50-day moving average price of $1.07 and a 200-day moving average price of $1.15.

Hedge Funds Weigh In On Connect Biopharma

Several institutional investors and hedge funds have recently bought and sold shares of CNTB. BML Capital Management LLC lifted its holdings in Connect Biopharma by 2.4% in the 3rd quarter. BML Capital Management LLC now owns 2,093,232 shares of the company's stock worth $3,014,000 after purchasing an additional 49,984 shares during the last quarter. Choreo LLC acquired a new stake in Connect Biopharma in the 4th quarter worth approximately $204,000. Callan Capital LLC lifted its holdings in Connect Biopharma by 91.3% in the 4th quarter. Callan Capital LLC now owns 80,000 shares of the company's stock worth $110,000 after purchasing an additional 38,177 shares during the last quarter. Finally, Catalina Capital Group LLC acquired a new stake in Connect Biopharma in the 4th quarter worth approximately $66,000. Hedge funds and other institutional investors own 58.72% of the company's stock.

About Connect Biopharma

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.